女性生殖系统癌症中的尿促性腺激素片段（UGF）。II. 初步系列研究。

Urinary gonadotropin fragments (UGF) in cancers of the female reproductive system. II. Initial serial studies.

作者信息

Wang Y X, Schwartz P E, Chambers J T, Cole L A

机构信息

Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut 06510.

出版信息

Gynecol Oncol. 1988 Sep;31(1):91-102. doi: 10.1016/0090-8258(88)90274-0.

DOI:10.1016/0090-8258(88)90274-0

PMID:3410359

Abstract

Levels of UGF, which constitute the free beta-subunit of human chorionic gonadotropin, asialo free beta-subunit, and a core fragment of asialo free beta-subunit, detected by a single immunoradiometric assay, were monitored in the urines of 28 woman undergoing therapy for gynecologic cancer (3 cervical, 8 endometrial, and 17 ovarian). During a 7-month study, 24 of the 28 woman had elevated UGF levels (greater than 0.2 ng/ml). Correlation was observed of UGF levels and changing clinical status during therapy in 23 of these 24. Normal range CA 125 (less than 35 U/ml) was found throughout the study period in 4 of 14 woman undergoing therapy for serous ovarian malignancy. Three of the 4 had elevated UGF levels which accurately followed the course of their disease. These preliminary studies suggest that in monitoring therapy of gynecologic cancers UGF, alone or with CA 125, warrants evaluation.

摘要

通过单一免疫放射分析检测到的人绒毛膜促性腺激素游离β亚基、去唾液酸游离β亚基以及去唾液酸游离β亚基核心片段（即UGF水平），在28名接受妇科癌症治疗的女性（3例宫颈癌、8例子宫内膜癌和17例卵巢癌）尿液中进行了监测。在为期7个月的研究中，28名女性中有24名UGF水平升高（大于0.2 ng/ml）。在这24名患者中的23名中，观察到UGF水平与治疗期间临床状态变化之间的相关性。在14名接受浆液性卵巢恶性肿瘤治疗的女性中，有4名在整个研究期间CA 125处于正常范围（小于35 U/ml）。这4名中的三名UGF水平升高，且准确地跟踪了疾病进程。这些初步研究表明，在监测妇科癌症治疗时，单独使用UGF或与CA 125联合使用，都值得评估。